Error loading player: No playable sources found
2060
AASLD Presidential Plenary
Date
May 18, 2024
This product is not available for individual purchase, but it is available as part of the following products:
Full DDW 2024 On Demand Program available now!
SOCIETY: AASLD
Presentations:
| ASSOCIATION OF GLUCAGON-LIKE PEPTIDE-1 AGONISTS WITH CIRRHOSIS AND HEPATOCELLULAR CANCER IN METABOLIC DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) |
| EFFICACY AND SAFETY OF SELADELPAR IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS IN THE ASSURE STUDY: INTERIM RESULTS |
| ALTERED GUT VIRAL ECOLOGY IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) |
| EFFECT OF EMPAGLIFLOZIN ON LIVER FAT IN METABOLIC-DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE PATIENTS WITHOUT DIABETES MELLITUS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL |
| PROJECTED PREVALENCE OF CIRRHOSIS AND OVERT HEPATIC ENCEPHALOPATHY IN THE UNITED STATES, 2021–2030 |
| EVALUATING THE IMPACT OF CO-EXISTING INFLAMMATORY BOWEL DISEASE IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS: A LARGE COHORT RETROSPECTIVE STUDY |
Moderators
Stanford University
Duke University
Speakers
Related Products
Predictors of Liver Disease Outcomes
SOCIETY: AASLD
AASLD Basic Science Emerging Topic Conference Day 1 $$$
SOCIETY: AASLD Join AASLD for an enlightening session where experts delve into groundbreaking research at the intersection of microbiome science and liver health…
Practice Guidelines (AASLD)
ACUTE ON CHRONIC LIVER FAILURE AND THE MANAGEMENT OF CRITICALLY ILL PATIENTS WITH CIRRHOSIS + Q&A
